modelMagnesiumOxide
Extends from Pharmacolibrary.Drugs.ATC.A.A02AA02.
Information
| name: | MagnesiumOxide | |
| ATC code: | A02AA02 | route: | oral |
| compartments: | 1 | |
| dosage: | 400 | mg |
| volume of distribution: | 0.25 | L |
| clearance: | 100 | ml/min |
| other parameters in model implementation | ||
Magnesium oxide is an inorganic compound used primarily as a mineral supplement for the treatment and prevention of magnesium deficiency. It is also commonly used as an antacid for the relief of heartburn and indigestion, and as a laxative for constipation. Magnesium oxide is approved for over-the-counter use in many countries for these indications.
Pharmacokinetics
Estimated oral pharmacokinetic parameters for healthy adults; specific pharmacokinetic studies for magnesium oxide as a distinct entity are scarce as magnesium is an essential mineral and drug absorption is highly variable and incomplete. Most reports focus on magnesium bioavailability or serum levels following supplementation.
References
Kashihara, Y, et al., & Ieiri, I (2019). Effects of magnesium oxide on pharmacokinetics of L-dopa/carbidopa and assessment of pharmacodynamic changes by a model-based simulation. European journal of clinical pharmacology 75(3) 351–361. DOI:10.1007/s00228-018-2568-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30382297
Hoy, SM, et al., & Wagstaff, AJ (2009). Sodium picosulfate/magnesium citrate: a review of its use as a colorectal cleanser. Drugs 69(1) 123–136. DOI:10.2165/00003495-200969010-00009 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19192941
Schuette, SA, et al., & Janghorbani, M (1994). Bioavailability of magnesium diglycinate vs magnesium oxide in patients with ileal resection. JPEN. Journal of parenteral and enteral nutrition 18(5) 430–435. DOI:10.1177/0148607194018005430 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7815675
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)